Sinonasal adenocarcinoma genomics (SNAG)
Research type
Research Study
Full title
Defining the mutational landscape of sinonasal adenocarcinoma
IRAS ID
372093
Contact name
Louise van der Weyden
Contact email
Sponsor organisation
Wellcome Sanger Institute
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Sinonasal adenocarcinoma (SNAC) is a rare type of cancer that develops in the lining of the nose and sinus cavities. It is often fast-growing and can be difficult to treat, with many patients having poor outcomes. Because this cancer is uncommon, there is currently no agreed standard treatment, and researchers still know little about the genetic changes that cause it.
Learning more about the genetic changes linked to SNAC could help researchers develop new treatments, identify people who may have a higher risk of developing the disease, and improve methods for earlier diagnosis or prevention. However, progress has been limited because the genetic features of this cancer have not yet been studied in detail.
This study aims to examine the DNA of SNAC tumour samples and nearby healthy tissue samples to better understand the genetic changes involved in the disease.
The study will use previously collected anonymous tissue samples from people diagnosed with SNAC. These samples will be identified by specialist head and neck pathologists from around the world. The DNA sequencing and analysis will be carried out at the Wellcome Sanger Institute.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
26/PR/0720
Date of REC Opinion
25 Jun 2026
REC opinion
Further Information Favourable Opinion